{"nctId":"NCT02767765","briefTitle":"A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy","startDateStruct":{"date":"2003-06"},"conditions":["Anemia"],"count":61,"armGroups":[{"label":"r-HuEPO","type":"EXPERIMENTAL","interventionNames":["Drug: r-HuEPO"]}],"interventions":[{"name":"r-HuEPO","otherNames":["NeoRecormon"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histological or cytological confirmed cancer\n* Participants who are treated with at least first line chemotherapy\n* Hemoglobin less than (\\<) 11 grams per deciliter (g/dL)\n* Participants able to receive iron supplement, if necessary\n\nExclusion Criteria:\n\n* History of hypersensitivity to active or inactive excipients of r-HuEPO\n* Insufficient controllable hypertension\n* Thalassemic syndromes\n* Anemia caused by hematic loss\n* Women who are pregnant or lactating","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Response to Treatment","description":"Response to treatment was defined as an increase of greater than (\\>) 1 gram per deciliter (g/dL) in hemoglobin level (irrespective of the need of transfusion) from Baseline value at Week 4.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Response","description":"Time to response was defined as the time between the start of treatment and the increase in hemoglobin level \\>1 g/dL compared to baseline hemoglobin level. Time to response was estimated using Kaplan Meier method.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Response to Treatment After 2 Weeks of Study Treatment","description":"Response to treatment after 2 weeks of treatment was defined as presence of any of the following criteria: reticulocytes \\>40000 per microliter or \\>25% increase in soluble transferrin receptor or \\>0.5 g/dL increase in hemoglobin level.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With No Response to Treatment After 4 Weeks of Study Treatment","description":"\"No Response\" to treatment after 4 weeks was defined as meeting any of the following criteria: \\<1 g/dL increase in hemoglobin level or hemoglobin level \\<8.5 g/dL or need of transfusion. If a participant had an increase in hemoglobin level of \\>1 g/dL but required transfusion then the participant is considered as Non- Responder.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Required Transfusion","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Questionnaire Score at Week 4","description":"FACT-An comprises of 4 subscales of 27-item (FACT-General scale \\[FACT-G\\]): physical well-being, social/family well-being, emotion well-being, functional well-being, and an additional concerns anemia subscale. All questions are rated on a scale from 0 to 4, where higher scores indicate more impact on quality of life. The physical well-being subscale consists of 7 questions with score range from 0-28; social/family well-being subscale consists of 7 questions with score range from 0-28; emotion well-being subscale consists of 6 questions with score range from 0-24; functional well-being subscale consists of 7 questions with score range from 0-28; anemia subscale consist of 20 questions with score range from 0-80. Total FACT-An score ranges from 0-188.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.59","spread":"10.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.23","spread":"8.11"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":61},"commonTop":["Anaemia","Abdominal pain","Gastric ulcer haemorrhage","Asthenia","Oedema peripheral"]}}}